熱門資訊> 正文
Pacira与强生签署合作伙伴关系，扩大Zilretta
2025-07-22 20:52
- 強生(JNJ) 0
- Pacira製藥(PCRX) 0
- 纳比特(NA) 0
- Pacira BioSciences (NASDAQ:PCRX) said it has partnered with Johnson & Johnson MedTech (NYSE:JNJ) to enhance the availability of Zilretta, a treatment designed for knee pain caused by osteoarthritis.
- This collaboration aims to utilize Johnson & Johnson's specialized sales team to promote Zilretta to both current and potential customers, the company said.
- Zilretta is known for its extended-release formula that helps manage knee pain effectively.
More on Pacira BioSciences, Johnson & Johnson
- Johnson & Johnson: The Worst Is Baked In
- Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
- Johnson & Johnson 2025 Q2 - Results - Earnings Call Presentation
- Johnson & Johnson seeks icotrokinra FDA approval
- Former biotech exec George Tidmarsh to lead key FDA drug center
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
